|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,939.55 INR | -0.22% |
|
+0.07% | +2.55% |
| Capitalization | 1,333B 14.76B 12.69B 11.83B 10.99B 20.51B 22.12B 136B 53.44B 637B 55.37B 54.23B 2,350B | P/E ratio 2026 * |
54.2x | P/E ratio 2027 * | 44.5x |
|---|---|---|---|---|---|
| Enterprise value | 1,350B 14.94B 12.84B 11.97B 11.13B 20.76B 22.39B 138B 54.09B 645B 56.04B 54.89B 2,379B | EV / Sales 2026 * |
10.4x | EV / Sales 2027 * | 9.08x |
| Free-Float |
30.26% | Yield 2026 * |
0.74% | Yield 2027 * | 0.87% |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | -0.22% | ||
| 1 week | +0.07% | ||
| Current month | +2.55% | ||
| 1 month | +3.97% | ||
| 3 months | +11.93% | ||
| 6 months | +18.91% | ||
| Current year | +2.55% |
| 1 week | 3,895.1 |  | 4,089.9 |
| 1 month | 3,700.05 | | 4,105.85 |
| Current year | 3,829.25 | | 4,105.85 |
| 1 year | 2,891.45 | | 4,105.85 |
| 3 years | 1,446.15 | | 4,105.85 |
| 5 years | 1,155.65 | | 4,105.85 |
| 10 years | 571.75 | | 4,105.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 2025-07-31 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 2018-08-31 |
| Compliance Officer | - | 2022-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 2014-07-29 | |
| Director/Board Member | 46 | 2018-02-07 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 2019-03-06 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.22% | +0.07% | +21.63% | +153.90% | 14.83B | |
| -0.35% | +1.24% | +35.07% | +197.88% | 968B | |
| +1.87% | +4.33% | +47.89% | +23.19% | 505B | |
| +0.32% | -1.42% | +24.90% | +43.72% | 389B | |
| -0.47% | +3.33% | +28.69% | +16.87% | 367B | |
| -0.79% | -0.21% | +29.44% | +20.18% | 295B | |
| -0.85% | -0.56% | +7.21% | -3.55% | 271B | |
| -0.18% | +1.90% | +25.17% | +34.49% | 274B | |
| +1.11% | +5.29% | -37.48% | -18.15% | 263B | |
| -0.38% | -1.78% | +20.03% | +19.35% | 175B | |
| Average | +0.12% | +2.31% | +20.25% | +48.79% | 352.3B | |
| Weighted average by Cap. | +0.38% | +2.29% | +25.51% | +68.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 130B 1.44B 1.24B 1.15B 1.07B 2B 2.16B 13.26B 5.21B 62.12B 5.4B 5.29B 229B | 147B 1.63B 1.4B 1.31B 1.21B 2.26B 2.44B 15.01B 5.9B 70.32B 6.11B 5.98B 259B |
| Net income | 24.32B 269M 231M 216M 201M 374M 403M 2.48B 975M 11.62B 1.01B 989M 42.87B | 30.2B 334M 287M 268M 249M 465M 501M 3.08B 1.21B 14.43B 1.25B 1.23B 53.22B |
| Net Debt | 16.24B 180M 155M 144M 134M 250M 269M 1.66B 651M 7.76B 674M 661M 28.63B | 2.96B 32.83M 28.21M 26.3M 24.44M 45.6M 49.18M 302M 119M 1.42B 123M 121M 5.22B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-13 | 3,939.55 ₹ | -0.22% | 2,821 |
| 26-01-12 | 3,948.25 ₹ | -0.37% | 1,637 |
| 26-01-09 | 3,962.85 ₹ | -1.55% | 2,204 |
| 26-01-08 | 4,025.10 ₹ | -1.62% | 5,441 |
| 26-01-07 | 4,091.25 ₹ | +3.92% | 21,964 |
Delayed Quote Bombay S.E., January 13, 2026 at 05:00 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 500420 Stock
Select your edition
All financial news and data tailored to specific country editions
